会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 41. 发明授权
    • System for detecting surrounding environmental conditions using a
multiple number of incoming signals
    • 使用多个输入信号检测周围环境条件的系统
    • US5001678A
    • 1991-03-19
    • US366513
    • 1989-06-15
    • Itsuo FukuokaHiroshi Nagano
    • Itsuo FukuokaHiroshi Nagano
    • G01S15/89G01S3/802G01S7/523
    • G01S3/8022Y10S367/903
    • A detection system forms a plurality of reception beams successively in angular directions by receiving incoming signals from various directions in a manner that the Doppler effect is produced to vary the carrier frequency of the incoming signals. The detection system displays underwater conditions on an indicator. To determine the underwater conditions, the detection system uses a plurality of ultrasonic transducers for receiving incoming signals, a plurality of preamplifiers for amplifying the reception signals produced by the ultrasonic transducers. A first coupling device which connects at least two of the ultrasonic transducers to a single preamplifier, and a matched filter for pulse-compressing reception signals produced by the ultrasonic transducers. A second coupling device successively couples the output terminals of the preamplifiers to an input terminal of the matched filter. The indicator displays output signals from the matched filter. The use of the first coupling device reduces the number of the preamplifiers.
    • 检测系统通过以产生多普勒效应以改变输入信号的载波频率的方式从各个方向接收输入信号而在角度方向上连续地形成多个接收波束。 检测系统在指示器上显示水下条件。 为了确定水下条件,检测系统使用多个超声换能器来接收输入信号,多个前置放大器用于放大由超声换能器产生的接收信号。 将至少两个超声换能器连接到单个前置放大器的第一耦合装置和用于脉冲压缩由超声换能器产生的接收信号的匹配滤波器。 第二耦合装置将前置放大器的输出端子连续地耦合到匹配滤波器的输入端子。 指示器显示匹配滤波器的输出信号。 使用第一耦合装置减少前置放大器的数量。
    • 42. 发明授权
    • Stretched polyester film from a polymer blend
    • 由聚合物共混物制成的拉伸聚酯膜
    • US4070417A
    • 1978-01-24
    • US642184
    • 1975-12-18
    • Tsutomu IsakaHiroshi NaganoTetsushi MurakamiKoichi MatsunamiYukio Yamane
    • Tsutomu IsakaHiroshi NaganoTetsushi MurakamiKoichi MatsunamiYukio Yamane
    • C08L67/00B29C49/00B29C55/00B29C55/02B32B27/32B32B27/36B41M1/30B65D33/00C08J5/18C08L67/02
    • C08L67/02B32B27/36B41M1/30C08L67/025
    • A transparent polyester film having excellent printability, flexing resistance and pinhole resistance and further excellent interlaminar strength, which is made from a polymer mixture or blend comprising (i) a polyester consisting essentially of a residue of dibasic acids wherein at least 80 % by mol is terephthalic acid and a residue of at least one glycol and (ii) a block copolyester consisting of a crystalline polyester (hard) segment having a high melting point and a soft polymer segment having a low melting point and a number average molecular weight of 400 to 8,000, said soft polymer segment having a low melting point being contained in an amount of 0.5 to 10 % by weight on the basis of the whole weight of the polymer mixture or blend, and said crystalline polyester segment having a melting point of at least 170.degree. C when a polymer is produced by the monomers composing the segment alone and said soft polymer segment having a melting or softening point of 100.degree. C or lower.
    • 一种由聚合物混合物或共混物制成的具有优异的可印刷性,抗弯曲性和针孔抗性以及更好的层间强度的透明聚酯薄膜,其包含(i)基本上由二元酸残基组成的聚酯,其中至少80摩尔% 对苯二甲酸和至少一种二醇的残基和(ii)由具有高熔点的结晶聚酯(硬)链段和软聚合物链段组成的嵌段共聚酯,所述软聚合物链段具有低熔点和数均分子量为400至 8,000,所述具有低熔点的所述软聚合物链段以基于聚合物混合物或共混物的全部重量的0.5至10重量%的量包含,并且所述结晶聚酯链段的熔点为至少170 当聚合物由单独构成段的单体和所述软聚合物链段的熔点或软化点为100℃或更低时产生时。
    • 44. 发明授权
    • Prophylactic or therapeutic agent for diabetic maculopathy
    • 预防或治疗糖尿病性黄斑病变
    • US08097640B2
    • 2012-01-17
    • US12842391
    • 2010-07-23
    • Noriaki KatoHiroshi NaganoKaori TanikoTakahito Jomori
    • Noriaki KatoHiroshi NaganoKaori TanikoTakahito Jomori
    • A01N43/50
    • A61K31/4166A01K2227/106A01K2267/0362A01K2267/0375C07D491/10G01N33/5088G01N2800/042
    • A prophylactic or therapeutic agent for diabetic maculopathy, which can be administered for a long time and exhibits efficacy in a mechanism different from that of existing medicines. The invention relates to a prophylactic or therapeutic agent for diabetic maculopathy, comprising, as an active ingredient, a compound represented by the general formula: wherein X represents a halogen or a hydrogen atom, R1 and R2 concurrently or differently represent a hydrogen atom or an optionally substituted C1 to C6 alkyl group, or R1 and R2, together with a nitrogen atom bound thereto and optionally another nitrogen atom or an oxygen atom, are combined to form a 5- to 6-membered heterocycle. Preferably, the compound is (2S,4S)-6-fluoro -2′,5′-dioxospiro chroman-4,4′-imidazolidine]-2-carboxamide. The invention also provides a model animal with diabetic maculopathy produced by subjecting a diabetic animal to intraocular ischemia/reperfusion to express edema in a retinal visual cell layer or in a macula lutea.
    • 用于糖尿病性黄斑病变的预防或治疗剂,其可以长时间施用并且以与现有药物不同的机制显示功效。 本发明涉及一种糖尿病性黄斑病变的预防或治疗剂,其特征在于,作为活性成分,含有下列通式表示的化合物:其中,X表示卤素或氢原子,R 1和R 2可以同时或不同地表示氢原子或 任选取代的C 1至C 6烷基,或R 1和R 2与连接的氮原子和任选另外的氮原子或氧原子一起形成5-至6-元杂环。 优选地,该化合物是(2S,4S)-6-氟-2',5'-二氧杂环苯并二氢吡喃-4,4'-咪唑烷] -2-甲酰胺。 本发明还提供了一种通过使糖尿病动物进行眼内缺血/再灌注以在视网膜视细胞层或黄斑黄斑中表达水肿而产生的糖尿病性黄斑变性的模型动物。
    • 45. 发明授权
    • Prophylactic or therapeutic agent for diabetic maculopathy
    • 预防或治疗糖尿病性黄斑病变
    • US07910615B2
    • 2011-03-22
    • US10587320
    • 2005-01-28
    • Noriaki KatoHiroshi NaganoKaori TanikoTakahito Jomori
    • Noriaki KatoHiroshi NaganoKaori TanikoTakahito Jomori
    • A01N43/50
    • A61K31/4166A01K2227/106A01K2267/0362A01K2267/0375C07D491/10G01N33/5088G01N2800/042
    • A prophylactic or therapeutic agent for diabetic maculopathy, which can be administered for a long time and exhibits efficacy in a mechanism different from that of existing medicines. The invention relates to a prophylactic or therapeutic agent for diabetic maculopathy, comprising, as an active ingredient, a compound represented by the general formula: wherein X represents a halogen or a hydrogen atom, R1 and R2 concurrently or differently represent a hydrogen atom or an optionally substituted C1 to C6 alkyl group, or R1 and R2, together with a nitrogen atom bound thereto and optionally another nitrogen atom or an oxygen atom, are combined to form a 5- to 6-membered heterocycle. Preferably, the compound is (2S,4S)-6-fluoro-2′,5′-dioxospiro[chroman-4,4′-imidazolidine]-2-carboxamide. The invention also provides a model animal with diabetic maculopathy produced by subjecting a diabetic animal to intraocular ischemia/reperfusion to express edema in a retinal visual cell layer or in a macula lutea.
    • 用于糖尿病性黄斑病变的预防或治疗剂,其可以长时间施用并且以与现有药物不同的机制显示功效。 本发明涉及一种糖尿病性黄斑病变的预防或治疗剂,其特征在于,作为活性成分,含有下列通式表示的化合物:其中,X表示卤素或氢原子,R 1和R 2可以同时或不同地表示氢原子或 任选取代的C 1至C 6烷基,或R 1和R 2与连接的氮原子和任选另外的氮原子或氧原子一起形成5-至6-元杂环。 优选地,化合物是(2S,4S)-6-氟-2',5'-二氧代螺[苯并二氢吡喃-4,4'-咪唑烷] -2-甲酰胺。 本发明还提供了一种通过使糖尿病动物进行眼内缺血/再灌注以在视网膜视细胞层或黄斑黄斑中表达水肿而产生的糖尿病性黄斑变性的模型动物。